VLON News and Press, Vallon Pharmaceuticals Inc. From 11/01/21

- Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant medication - Company’s l ead investigational program...

- L ead program, ADAIR , advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR - Company’s t wo lead ...

- Inaugural a ppointments include globally renowned leaders and experts on attention-deficit/hyperactivity disorder (ADHD) and stimulant abuse PHILADELPHIA, PA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON)...

Shares of Vallon Pharmaceuticals Inc. (NASDAQ:VLON) traded today at $10.20, eclipsing its 52-week high. This new high was reached on above average trading volume as 535,000 shares traded hands, while the average 30-day volume is approximately 309,000 shares. Vallon Pharmaceuticals Inc. (...

Gainers: Regional Health Properties (NYSE:RHE) +55%. AC Immune (NASDAQ:ACIU) +34%. Net Element (NASDAQ:NETE) +27%. Vallon Pharmaceuticals (NASDAQ:VLON) +25%. Spok (NASDAQ:SPOK) +23%. Elys Game Technology (NASDAQ:ELYS) +21%. Youdao (NYSE:DAO) +20%. Qualigen Therapeutics (NASDAQ:QLGN) +18%. Azu...

Live video webcast with David Baker, President and CEO of Vallon , on Wednesday , August 18 th 12 : 30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (&#...

- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall ® segment of the ~$9 billion US ADHD market PHILADE...

Vallon Pharmaceuticals ([[VLON]] -6.1%) announces that the European Patent Office has issued patent number EP3576719B1 covering ADAIR, the Company’s proprietary abuse-deterrent formulation of immediate-release dextroamphetamine.The new European patent covers composition of matter and m...

- Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon...

Vallon Pharmaceuticals (VLON): Q1 net loss of $2.6MCash and cash equivalents of ~$13.0M, which the Company expects will provide funding for its ongoing business activities into the third quarter of 2022.Shares are up 2.67% PM.Press Release For further details see: Vallon Pharm...